Renal Cell Carcinoma (RCC) has historically been considered a radioresistant cancer, and radiotherapy was usually delivered with a palliative goal. Stereotactic ablative radiotherapy (SABR) allows the delivery of high doses on small treatment volumes in a safe and effective way, thus opening the doors to new applicationsof radiotherapy both in the treatment of the primary and oligometastasic disease. Aim of the current review is to explore the state of art of SABR in the therapeutic approach to RCC.
Critical reviews in oncology/hematology. 2017 Jul 13 [Epub]
Filippo Alongi, Stefano Arcangeli, Luca Triggiani, Rosario Mazzola, Michela Buglione di Monale E Bastia, Sergio Fersino, Anna Baiguini, Barbara Alicja Jereczek-Fossa, Stefano Maria Magrini, on the behalf of Italian Association of Radiation Oncology [AIRO]
Radiation Oncology, Sacro Cuore Don Calabria Cancer Care Center, Negrar-Verona, Italy; University of Brescia, Brescia, Italy., Radiation Oncology, San Camillo and Forlanini Hospital, Rome, Italy., Radiation Oncology, Spedali Civili of Brescia, Brescia, Italy., Radiation Oncology, Sacro Cuore Don Calabria Cancer Care Center, Negrar-Verona, Italy. Electronic address: ., Radiation Oncology, Sacro Cuore Don Calabria Cancer Care Center, Negrar-Verona, Italy., Radiation Oncology, European Institute of Oncology, University of Milan, Milan, Italy.